NYSE: TEVATeva Pharmaceutical Industries Ltd Stock
$13.31-0.34 (-2.49%)
Updated Apr 21, 2025
TEVA Price
$13.31
Fair Value Price
N/A
Market Cap
$15.09B
52 Week Low
$12.47
52 Week High
$22.80
P/E
-9.18x
P/B
2.81x
P/S
1.51x
PEG
N/A
Dividend Yield
N/A
Revenue
$16.54B
Earnings
-$1.64B
Gross Margin
48.7%
Operating Margin
0.11%
Profit Margin
-9.9%
Debt to Equity
6.26
Operating Cash Flow
$1B
Beta
0.89
Next Earnings
May 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
TEVA Overview
Teva Pharmaceutical Industries Limited manufactures,and distributes generic medicines, specialty medicines, and biopharmaceutical products in the U.S. and internationally. Offerings include sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms (tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams). Teva focuses on the central nervous system, pain, respiratory, and oncology areas. Its product, Copaxone, treats relapsing forms of multiple sclerosis. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TEVA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
TEVA
Ranked#36 of 54
Ranked#36 of 54
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.13 | A | |
| $13.89 | A | |
| $30.29 | A |
Be the first to know about important TEVA news, forecast changes, insider trades & much more!
TEVA News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TEVA scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TEVA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TEVA is poor value based on its book value relative to its share price (2.81x), compared to the US Drug Manufacturers - Specialty & Generic industry average (1.98x)
P/B vs Industry Valuation
TEVA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 35 more TEVA due diligence checks available for Premium users.
Valuation
TEVA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-9.18x
Industry
20.59x
Market
27.14x
TEVA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.81x
Industry
1.98x
TEVA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TEVA's financial health
Profit margin
Revenue
$4.2B
Net Income
-$217.0M
Profit Margin
-5.1%
TEVA's Earnings (EBIT) of $18.00M... subscribe to Premium to read more.
Interest Coverage Financials
TEVA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$39.3B
Liabilities
$33.6B
Debt to equity
6.26
TEVA's short-term liabilities ($12.80B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TEVA's long-term liabilities ($20.81B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TEVA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
TEVA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$575.0M
Investing
$202.0M
Financing
-$674.0M
TEVA's operating cash flow ($1.25B)... subscribe to Premium to read more.
Debt Coverage Financials
TEVA vs Pharmaceutical Stocks
Teva Pharmaceutical Industries Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.